Second dose of experimental drug may help when first fails

NCT ID NCT07039422

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether a second course of ianalumab can help adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who previously responded to the drug but then stopped responding. About 60 participants will receive ianalumab by IV infusion. The goal is to see if it can control the disease again without major side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (a biologic drug given by IV infusion)
What this could lead to: If successful, this could show that a second course of ianalumab helps control ITP or wAIHA when the first course stops working.
What could go wrong: This is a small, early-phase study (60 people) with no placebo group, so results may not be definitive. Risks include infusion reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia, warm type autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNE THROMBOCYTOPENIA WARM AUTOIMMUNE HEMOLYTIC ANEMIA

Contacts and locations

Locations

Novartis Investigative Site
WITHDRAWN

Buenos Aires, C1039AAC, Argentina
Novartis Investigative Site
RECRUITING

Roeselare, West-Vlaanderen, 8800, Belgium
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Dalian, Liaoning, 116023, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China
Novartis Investigative Site
RECRUITING

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site
RECRUITING

Caen, 14033, France
Novartis Investigative Site
RECRUITING

Rennes, 35033, France
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site
RECRUITING

Florence, FI, 50134, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00168, Italy
Novartis Investigative Site
RECRUITING

Trieste, TS, 34129, Italy
Novartis Investigative Site
RECRUITING

Vicenza, VI, 36100, Italy
Novartis Investigative Site
RECRUITING

George Town, 10050, Malaysia
Novartis Investigative Site
RECRUITING

Johor Bahru, 80100, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site
RECRUITING

Bucharest, 030171, Romania
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28009, Spain
Novartis Investigative Site
RECRUITING

Murcia, 30008, Spain
Novartis Investigative Site
RECRUITING

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Ankara, Bilkent Cankaya, 06800, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.